Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.36 |
| ▸ | PLAU | P00749 | 1/20 | 0.33 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | MEF2D | Q14814 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4161500 | 1.00 | HMGCR (0.42) | HMGCRTAAR1PLAUAKR1B10AKR1B1 | |
| SCHEMBL4161502 | 1.00 | HMGCR (0.42) | HMGCRTAAR1PLAUAKR1B10AKR1B1 | |
| SCHEMBL4185693 | 1.00 | HMGCR (0.42) | HMGCRTAAR1PLAUAKR1B10AKR1B1 | |
| SCHEMBL4169128 | 0.99 | HMGCR (0.43) | HMGCRTAAR1PLAUAKR1B10AKR1B1 | |
| SCHEMBL4169135 | 0.99 | HMGCR (0.43) | HMGCRTAAR1PLAUAKR1B10AKR1B1 | |
| SCHEMBL4166584 | 0.75 | TLR4 (0.39) | TAAR1MAOA | |
| SCHEMBL4166580 | 0.75 | TLR4 (0.39) | TAAR1MAOA | |
| SCHEMBL4170113 | 0.74 | PNMT (0.31) | — | |
| SCHEMBL4170106 | 0.74 | PNMT (0.31) | — | |
| SCHEMBL17032808 | 0.74 | PNMT (0.40) | TAAR1DRD2DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120129860-A1 | STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2012-05-24 | — | — | US | claimed |
| EP-2076124-A2 | STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | Acucela, Inc. (US) | 2009-07-08 | — | — | EP | claimed |
| WO-2008131368-A2 | STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2008-10-30 | — | — | WO | claimed |
| US-10201545-B2 | Styrenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-9421210-B2 | Styrenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-20160193160-A1 | Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders | ACUCELA INC. | 2016-07-07 | — | — | US | disclosed |
| US-9314467-B2 | Styrenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-20150238497-A1 | STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2015-08-27 | — | — | US | disclosed |
| US-20150166494-A1 | Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders | ACUCELA INC. | 2015-06-18 | — | — | US | disclosed |
| US-20150166495-A1 | Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders | ACUCELA INC. | 2015-06-18 | — | — | US | disclosed |
| US-8653142-B2 | Styrenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-20130253064-A1 | STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2013-09-26 | — | — | US | disclosed |
| US-8420863-B2 | Styrenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-20120129860-A1 | STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| EP-2076124-A2 | STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | Acucela, Inc. (US) | 2009-07-08 | — | — | EP | disclosed |
| US-20090170841-A1 | Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders | ACUCELA INC. (US) | 2009-07-02 | — | — | US | disclosed |
| WO-2008131368-A2 | STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166495-A1 | Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders | ALDH1A2, STARD3, TXNRD2 | HMGCR 313/4885TAAR1 2715/4885PLAU 4393/4885 |
| US-20150166494-A1 | Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders | ALDH1A2, STARD3, TXNRD2 | HMGCR 313/4885TAAR1 2715/4885PLAU 4393/4885 |
| US-20120129860-A1 | STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ALDH1A2, STARD3, TXNRD2 | HMGCR 313/4885TAAR1 2715/4885PLAU 4393/4885 |
| US-20130253064-A1 | STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ALDH1A2, STARD3, TXNRD2 | HMGCR 313/4885TAAR1 2715/4885PLAU 4393/4885 |
| US-20150238497-A1 | STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ALDH1A2, STARD3, TXNRD2 | HMGCR 313/4885TAAR1 2715/4885PLAU 4393/4885 |
| US-20160193160-A1 | Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders | ALDH1A2, STARD3, TXNRD2 | HMGCR 313/4885TAAR1 2715/4885PLAU 4393/4885 |
| US-10201545-B2 | Styrenyl derivative compounds for treating ophthalmic diseases and disorders | ALDH1A2, STARD3, TXNRD2 | HMGCR 313/4885TAAR1 2715/4885PLAU 4393/4885 |
| US-20090170841-A1 | Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders | ALDH1A2, STARD3, TXNRD2 | HMGCR 313/4885TAAR1 2715/4885PLAU 4393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.